Table 5. Correlation of interaction of EZH2 rs12670401, EZH2 rs6464926, and SMYD3 VNTR gene polymorphisms with breast cancer susceptibility in the case and control groups.
| Combined genotype | Case group, n (%) | Control group, n (%) | OR | 95% CI | P |
|---|---|---|---|---|---|
| EZH2 rs12670401 (TC + CC)/EZH2 rs6464926 (CT + TT) | 316 (44.41) | 303 (38.76) | 1.465 | 1.055–2.036 | 0.022 |
| EZH2 rs12670401 (TC + CC)/EZH2 rs6464926 (CC) | 164 (23.01) | 190 (24.20) | 1.213 | 0.849–1.732 | 0.288 |
| EZH2 rs12670401 (TT)/EZH2 rs6464926 (CT + TT) | 153 (21.46) | 179 (22.80) | 1.201 | 0.838–1.722 | 0.319 |
| EZH2 rs12670401 (TT)/EZH2 rs6464926 (CC) | 79 (11.12) | 111 (14.24) | Reference | ||
| EZH2 rs12670401 (TC + CC)/ SMYD3VNTR(2/3 + 3/3) | 192 (26.99) | 99 (12.69) | 1.312 | 0.918–1.874 | 0.136 |
| EZH2 rs12670401 (TC + CC)/ SMYD3VNTR (2/2) | 288 (40.43) | 160 (20.44) | 1.217 | 0.879–1.685 | 0.236 |
| EZH2 rs12670401 (TT)/ SMYD3VNTR(2/3 + 3/3) | 93 (13.04) | 58 (7.47) | 1.084 | 0.713–1.650 | 0.705 |
| EZH2 rs12670401 (TT)/ SMYD3VNTR (2/2) | 139 (19.54) | 94 (12.02) | Reference | ||
| SMYD3VNTR(2/3 + 3/3)/EZH2 rs6464926 (CT + TT) | 188 (26.37) | 185 (44.82) | 1.288 | 0.957–1.733 | 0.095 |
| SMYD3VNTR (2/3 + 3/3)/EZH2 rs6464926 (CC) | 97 (13.66) | 115 (27.99) | 1.069 | 0.756–1.512 | 0.707 |
| SMYD3VNTR (2/2)/EZH2 rs6464926 (CT + TT) | 281 (39.50) | 297 (72.17) | 1.195 | 0.911–1.567 | 0.198 |
| SMYD3VNTR (2/2)/EZH2 rs6464926 (CC) | 146 (20.47) | 186 (45.07) | Reference |
Reference, 95% CI is 1.